{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T02:24:11Z","timestamp":1751509451838,"version":"3.37.3"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The American Thoracic Society Guidelines recommend vancomycin as first line option for treatment of methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic>. Two studies have described the pharmacokinetics (PK) of intermittent intravenous (IV) vancomycin in adult people with cystic fibrosis (PwCF). Currently, there have not been any studies describing the PK of continuous infusion vancomycin in PwCF. Our study aimed to describe the PK of continuous infusion vancomycin in adult PwCF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Included patients were adult PwCF, who were admitted to University of Utah Hospital between May 11, 2014 and August 31, 2020, and received continuous infusion vancomycin for the treatment of an pulmonary exacerbations. The primary outcome was to describe vancomycin clearance rate (CL<jats:sub>vanco<\/jats:sub>) and total daily dose (TDD). Secondary outcomes included rates of acute kidney injury (AKI), liver injury, and infusion\u2010related reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients were included in this study. The mean CL<jats:sub>vanco<\/jats:sub> was 5.08\u2009L\/h on Day 3 and 4.58\u2009L\/h on Day 7 (<jats:italic>p<\/jats:italic>\u2009=\u2009.04), and the TDD increased from 2444\u2009mg on Day 3 to 2556 on Day 7, although not statistically significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.26). Zero patients experienced an AKI, two patients experienced liver injury, and no patients experienced infusion\u2010related reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrates that continuous infusion vancomycin PK, namely CL<jats:sub>vanco<\/jats:sub>, is similar to previously reported CL<jats:sub>vanco<\/jats:sub> for intermittent dosed IV vancomycin in adult PwCF. This study suggests that continuous infusion vancomycin is likely safe to use in adult PwCF.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.26714","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:13:56Z","timestamp":1696432436000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis"],"prefix":"10.1002","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5861-4441","authenticated-orcid":false,"given":"Bryn","family":"Lindley","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy University of North Texas Health Science Center College of Pharmacy Fort Worth Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubin","family":"Bhakta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Utah Health Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Leclair","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Utah Health Salt Lake City Utah USA"},{"name":"University of Utah School of Medicine Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Utah Health Salt Lake City Utah USA"},{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1836157"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201402-050AS"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014567526"},{"key":"e_1_2_10_6_1","unstructured":"Dynamed.Cystic fibrosis (CF). Accessed July 23 2020.2018.https:\/\/www.dynamed.com\/condition\/cystic-fibrosis-cf"},{"volume-title":"Cystic Fibrosis Foundation Patient Registry, 2019 Annual Data Report","year":"2019","author":"Marshall B","key":"e_1_2_10_7_1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-327OC"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20604"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.08.006"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004326"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.10.019"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618768749"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.186"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26077"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc2872"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","unstructured":"HongLT LiouTG DekaR KingJB StevensV YoungDCPharmacokinetics of continuous infusion beta\u2010lactams in the treatment of acute pulmonary exacerbations in adult patients with cystic fibrosis.Chest2018;154(5):1108\u20101114.","DOI":"10.1016\/j.chest.2018.06.002"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.26714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T13:13:33Z","timestamp":1703855613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.26714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/ppul.26714"],"URL":"https:\/\/doi.org\/10.1002\/ppul.26714","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"type":"print","value":"8755-6863"},{"type":"electronic","value":"1099-0496"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"2023-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}